港股异动 | 科伦博泰生物-B(06990)涨超4% ITGB6等两款候选药于明年一季度开展I/II期单药治疗临床试验

智通财经
Dec 11, 2025

智通财经APP获悉,科伦博泰生物-B(06990)涨超4%,截至发稿,涨3.69%,报427.4港元,成交额1831.69万港元。

消息面上,近日,科伦博泰生物和Crescent达成合作,共同开发及商业化新型肿瘤治疗手段(含新型联用疗法),合作涉及科伦博泰生物的一款靶向整合素β6(ITGB6)并以拓扑异构酶抑制剂为载荷ADC药物SKB105(CR-003),以及Crescent的一款PD-1xVEGF 双特异性抗体CR-001(SKB118)。这两款候选药物正在开发用于治疗实体瘤,预计于2026年第一季度开展I/II期单药治疗临床试验。

天风证券指出,科伦博泰生物与Crescent合作内容包括分别推进两款候选药物的单药治疗开发,并共同评估CR-001与SKB105的联用疗法。双方均有权独立开发CR-001的其他联用方案。CR-001是一款四价双特异性抗体,在临床前研究中显示强大的抗肿瘤活性。

对价方面,科伦博泰生物将从Crescent 获得8,000万美元首付款,并有资格获得最高累计12.5亿美元的里程碑付款,以及基于SKB105净销售额按中个位数至低双位数比例浮动的分级特许权使用费。如Crescent在近期发生控制权变更或与第三方达成分许可安排,科伦博泰生物亦有资格收取额外对价。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10